Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.

While statistical testing was not performed, there was a numerical trend for patients in the self‐administration group to be younger than those in the HCP group (median age of 53 vs 58 years, respectively) and with a longer median time since primary ITP diagnosis (3.7 vs 2.5 years, respectively).

also in 1,012 other papers